Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.
Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.
Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data
Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.
Castle Biosciences (NASDAQ: CSTL) will showcase its skin cancer diagnostic tests at Maui Derm for Dermatologists 2022 from January 24-28, 2022, in Maui, Hawaii. Key presentations include the integration of a 31-gene expression profile for melanoma risk assessment and the appropriate use of a 40-gene expression profile test for cutaneous squamous cell carcinoma. The DecisionDx-Melanoma and DecisionDx-SCC tests aim to enhance patient management by predicting metastatic risks. These tests have been validated in numerous studies, indicating their reliability in clinical settings.
Castle Biosciences (CSTL) announced a clinical performance study published in Future Oncology, showcasing the DecisionDx-SCC test's ability to independently assess metastasis risk in patients with cutaneous squamous cell carcinoma (SCC).
The study involved 420 cases and revealed significant stratification of risk, with metastasis rates of 6.6%, 20.0%, and 52.2% for Class 1, 2A, and 2B results, respectively. The findings suggest that integrating DecisionDx-SCC enhances risk prediction for individualized patient management.
Castle Biosciences, Inc. (CSTL) announces the publication of a study validating the DecisionDx-UMSeq panel, enhancing uveal melanoma diagnostics. This 7-gene test leverages next-generation sequencing to identify critical somatic mutations from a single biopsy. Results show 100% positive agreement for single nucleotide variants and high technical prediction values. The combined use of DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq allows for comprehensive tumor profiling, aiding in better-informed patient care and management decisions.
Castle Biosciences (CSTL) expects 2021 revenue to meet or exceed
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present at the 24th Annual Needham Growth Conference on January 10, 2022, at 12:30 p.m. Eastern time. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks thereafter. Castle Biosciences specializes in personalized diagnostics for diseases such as skin cancer and has an innovative test development pipeline aimed at improving treatment outcomes.
Castle Biosciences has announced the acquisition of Cernostics for approximately
Castle Biosciences, Inc. (NASDAQ: CSTL) presented its DecisionDx® gene expression profile tests for skin cancer at the American Society for Dermatologic Surgery 2021 Annual Meeting (Nov. 19-21, 2021). These tests, including DecisionDx-Melanoma and DecisionDx-SCC, aim to enhance personalized treatment decisions and patient outcomes. Key findings indicated that integrating genetic data with clinical features can better predict metastasis and recurrence risks. The studies support the clinical utility of these tests in managing melanoma and cutaneous squamous cell carcinoma.
Castle Biosciences (NASDAQ:CSTL) announced a study showcasing its DecisionDx-Melanoma test's predictive capabilities in cutaneous melanoma. The study, involving 438 patients, revealed that those classified as Class 1A (low risk) achieved a remarkable five-year recurrence-free survival rate of 95.8% and a distant metastasis-free survival rate of 99.2%. This underscores the test's role in aiding personalized treatment decisions and improving patient outcomes, with significant independent predictive value over traditional staging methods.